TNF-R2 was chosen as the highly elevated biomarker in VS patients, MCP-3 was selected as the only verified factor significantly associated with SH and WR, S100B is a phenotypic marker of VS correlating with tumor size, and MIF, CD30, IL-2R, BLC, TWEAK, and eotaxin were selected based on their contribution to improving the predictability (panel AUC) of the other biomarkers. This evidence concerns the gene S100B and neoplasm.